These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 37408838)

  • 1. The gut-liver axis in immune remodeling of hepatic cirrhosis.
    Guan H; Zhang X; Kuang M; Yu J
    Front Immunol; 2022; 13():946628. PubMed ID: 37408838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiota, cirrhosis, and the emerging oral-gut-liver axis.
    Acharya C; Sahingur SE; Bajaj JS
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of microbiome in patients with decompensated cirrhosis.
    Oikonomou T; Papatheodoridis GV; Samarkos M; Goulis I; Cholongitas E
    World J Gastroenterol; 2018 Sep; 24(34):3813-3820. PubMed ID: 30228776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases.
    Yang X; Lu D; Zhuo J; Lin Z; Yang M; Xu X
    Int J Biol Sci; 2020; 16(13):2357-2366. PubMed ID: 32760203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gut microbiota-bile acid axis in cholestatic liver disease.
    Sun D; Xie C; Zhao Y; Liao J; Li S; Zhang Y; Wang D; Hua K; Gu Y; Du J; Huang G; Huang J
    Mol Med; 2024 Jul; 30(1):104. PubMed ID: 39030473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut-liver axis: Pathophysiological concepts and clinical implications.
    Tilg H; Adolph TE; Trauner M
    Cell Metab; 2022 Nov; 34(11):1700-1718. PubMed ID: 36208625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis.
    Woodhouse C; Singanayagam A; Patel VC
    Clin Med (Lond); 2020 Sep; 20(5):493-500. PubMed ID: 32934044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy
    Luo M; Xin RJ; Hu FR; Yao L; Hu SJ; Bai FH
    World J Gastroenterol; 2023 Jan; 29(1):144-156. PubMed ID: 36683714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
    Stecher B
    Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the gut-liver-immune axis to treat cirrhosis.
    Tranah TH; Edwards LA; Schnabl B; Shawcross DL
    Gut; 2021 May; 70(5):982-994. PubMed ID: 33060124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.
    Maslennikov R; Poluektova E; Zolnikova O; Sedova A; Kurbatova A; Shulpekova Y; Dzhakhaya N; Kardasheva S; Nadinskaia M; Bueverova E; Nechaev V; Karchevskaya A; Ivashkin V
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease.
    Maccioni L; Leclercq IA; Schnabl B; Stärkel P
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.
    Bajaj JS; Betrapally NS; Hylemon PB; Heuman DM; Daita K; White MB; Unser A; Thacker LR; Sanyal AJ; Kang DJ; Sikaroodi M; Gillevet PM
    Hepatology; 2015 Oct; 62(4):1260-71. PubMed ID: 25820757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
    Jiang JW; Chen XH; Ren Z; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered Microbiome in Patients With Cirrhosis and Complications.
    Acharya C; Bajaj JS
    Clin Gastroenterol Hepatol; 2019 Jan; 17(2):307-321. PubMed ID: 30099098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.